Teva's late-stage pipeline includes duvakitug and DARI ... OTC business with a global portfolio of strong local and global brands, outperforming the market with double-digit growth.

Teva outlines ... LAI, duvakitug, DARI, and emrusolmin. AUSTEDO : Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030. AJOVY : A globally established brand with presence ...

TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva ... LAI, duvakitug, DARI, and emrusolmin. AUSTEDO: Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion ...

Teva outlines acceleration ... assets including olanzapine LAI, duvakitug, DARI, and emrusolmin. AUSTEDO: Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030. AJOVY: A ...

Druckenmiller Did Increase His Stake in Teva Pharmaceuticals by 530% One of his most recent standout buys was brand name and generic ... data of its promising drug Duvakitug, which is being ...

It is my privilege to kick off our Spec Pharma track with Teva Pharmaceuticals ... obviously the headlines of Duvakitug, but olanzapine and no PDSS, bringing UZEDY to the market, ICS/SABA are ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s innovative pipeline is promising, with late-stage products such as Duvakitug ... Among the well-known brands in its portfolio are Benavides ...

In ulcerative colitis, duvakitug led to clinical remission in ... Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ...